A Case of Nivolumab-Induced Myositis
نویسندگان
چکیده
Introduction TheMay2016issueofTheOncologistsummarizesU.S.Foodand Drug Administration approval for nivolumab in non-small cell lung cancer [1]. In response, we present a case of nivolumabinducedmyositis, an unlisted side effect that has been reported only once previously. Nivolumab (Opdivo) is a monoclonal antibody classified as an immune modulator. It binds to programmed cell death-1 (PD-1) and blocks the PD-1 pathway, allowing immune cells to attack a tumor efficiently [2].
منابع مشابه
Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer
RATIONALE Immune checkpoint inhibitors have led to the development of new approaches for cancer treatment with positive outcomes. However, checkpoint blockade is associated with a unique spectrum of immune-related adverse events (irAEs), which may cause irreversible neurological deficits and even death. PATIENT CONCERNS We presented a case of a 57-year-old man with non-small-cell lung cancer....
متن کاملMyasthenic crisis and polymyositis induced by one dose of nivolumab
An 80-year-old man, who developed multiple lymph node and skin metastasis of malignant melanoma, received nivolumab monotherapy. Two weeks after the first dose, he experienced anorexia and fatigue, and suffered from progressive, severe dyspnea and muscle weakness. We diagnosed him with myocarditis, myositis, and myasthenic crisis induced by nivolumab. We commenced steroid therapy, immune absorp...
متن کاملHigh incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review
BACKGROUND Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (irAEs), including pneumonitis. CASE PRESENTATION We present a case series of four patients with malignant ...
متن کاملNivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma
RATIONALE Nivolumab (Nivo) is an immune checkpoint inhibitor that has been used to treat advanced melanoma, nonsmall cell lung carcinoma, and renal cell carcinoma since 2015. Nivo is associated with several side effects, including hepatitis, pneumonitis, acute renal failure, endocrine disorder, and other immune-related adverse events. Here, we describe the case of a 65-year-old man with squamou...
متن کاملNivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient
BACKGROUND Nivolumab is an anti-PD-1 immune checkpoint inhibitor that was recently developed for cancer immunotherapy. In the clinical trials of nivolumab, its adverse effects were reported to be less likely than those of conventional anti-cancer agents; however, after practical clinical distribution, it has come to be known that nivolumab induces various immune-related adverse events. CASE REP...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 21 شماره
صفحات -
تاریخ انتشار 2016